Insiders Revance Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
4.29 ^USD	+0.47%		+13.79%	-51.19%

05-09	Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M	MT
05-04	Certain Restricted Stock Units of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	CI

Revance Therapeutics, Inc. Announces Executive Changes	02-28	CI
Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics	11-08	CI
Insider Sell: Revance Therapeutics	07/09/23	MT
Insider Sell: Revance Therapeutics	04/08/23	MT
Insider Sell: Revance Therapeutics	02/05/23	MT
Revance Therapeutics, Inc. Announces Board Changes	28/02/23	CI
Revance Therapeutics, Inc. Appoints David A. Hollander as Chief Medical Officer	17/10/22	CI
Insider Sell: Revance Therapeutics	16/09/22	MT
Revance Therapeutics, Inc. Announce Resignation of Aubrey Rankin as A Member of the Board of Directors	24/03/22	CI
Revance Therapeutics, Inc. Announces Executive Changes	28/02/22	CI
Insider Buy: Revance Therapeutics	30/11/21	MT
Revance Therapeutics, Inc. Promotes Dustin Sjuts as President	09/11/21	CI
Subsea 7 S A : Appoints Successor to Retiring CFO	14/09/21	MT
Insider Trends: Revance Therapeutics Insider Extends 90-Day Selling Trend	31/07/21	MT
Insider Trends: Revance Therapeutics Insider Extends 90-Day Selling Trend	29/07/21	MT
Revance Announces Board Changes	22/02/21	CI
Insider Trends: Insider 90-Day Selling Trend Extended at Revance Therapeutics	04/02/21	MT
Insider Trends: Insider Disposition Eases Back 90-Day Buy Trend at Revance Therapeutics	03/12/20	MT
Insider Trends: Revance Therapeutics Insider Sale Scales Back 90-Days of Buys	31/10/20	MT
Revance Therapeutics, Inc. Appoints Aubrey Rankin as Director and President of Innovation & Technology	24/07/20	CI

No results for this search